Cancer immunomodulation using bispecific aptamers
Brian J. Thomas, David Porciani, Donald H. Burke
Abstract
pre-clinical models. We discuss these advances here, along with gaps in bsApt biology at both the cellular and resident tissue levels that should be addressed to accelerate their translation into the clinic. The broad application, minimal production cost, and relative lack of immunogenicity of bsApts give them some ideal qualities for manipulating the immune system. Building upon lessons from other novel therapies, bsApts could soon provide clinicians with an immunomodulating toolbox that is not only potent and efficacious but exercises a wide therapeutic index.
Topics & Concepts
AptamerCancerComputational biologyCancer researchComputer scienceMedicineBiologyInternal medicineMolecular biologyAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene DeliveryMonoclonal and Polyclonal Antibodies Research